Current Headlines

  1. Asterand Bioscience And MolecularMD Announce A Partnership To Accelerate Targeted Therapeutic Biomarker Validation, Optimization, Development And Commercialization
    2/15/2017

    Asterand Bioscience, the leader in high quality, well-characterized human tissue and human tissue-based research solutions supporting drug discovery and development, announced recently a partnership with MolecularMD to combine MolecularMD’s expertise as a provider of molecular diagnostics products and services with Asterand Bio’s drug target and candidate validation capabilities

  2. X-Chem Expands Collaboration With Janssen In Inflammatory Diseases
    2/15/2017

    X-Chem, Inc. (X-Chem) announced recently that it has expanded its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new drug leads for the treatment of inflammatory disease

  3. Versant Ventures Launches Jecure Therapeutics
    2/15/2017

    Versant Ventures recently announced the debut of Jecure Therapeutics, a biotechnology company with a proprietary liver disease platform that has generated novel programs for non-alcoholic steatohepatitis (NASH) and fibrosis

  4. FDA Grants PMA Approval For Hologic's Aptima® Hepatitis C Quant Dx Assay
    2/15/2017

    Hologic, Inc. (Nasdaq: HOLX) announced today that the United States Food and Drug Administration (FDA) has granted PMA approval for the Company's hepatitis C virus (HCV) assay for quantitation of HCV viral load and confirming active HCV infection on the fully automated Panther® system

  5. Boehringer Ingelheim And Weill Cornell Medicine Announce New Collaboration To Discover Next Generation COPD Treatments
    2/15/2017

    Boehringer Ingelheim recently announced a collaboration with Weill Cornell Medicine to identify new treatment approaches forchronic obstructive pulmonary disease (COPD) in order to develop novel treatments that could possibly halt or even reverse the progression of the disease process

  6. Viking Therapeutics And PoC Capital Enter Agreement To Fund Clinical Development Of VK2809 In Glycogen Storage Disease Ia (GSD Ia)
    2/14/2017

    Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced an agreement with PoC Capital, LLC to fund Viking's initial clinical development of VK2809 in glycogen storage disease type Ia (GSD Ia)

  7. Theratechnologies Announces New Data From The Pivotal Phase III Trial Of HIV Monoclonal Antibody And Long-Acting Investigational Antiretroviral Ibalizumab
    2/14/2017

    Theratechnologies Inc. (Theratechnologies) (TSX: TH) announced today that additional secondary efficacy and safety endpoint results from the 24-week ibalizumab Phase III trial, TMB-301, were presented at a late-breaker session at the Conference on Retroviruses and Opportunistic Infections (CROI) 2017

  8. Amgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    2/14/2017

    Amgen (NASDAQ: AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for BLINCYTO® (blinatumomab) to include overall survival (OS) data from the Phase 3 TOWER study, supporting the conversion of BLINCYTO's accelerated approval to full approval

  9. XTL Biopharmaceuticals Expands Clinical Advisory Board To Support Phase II Study Of HCDR1 In Sjogren's Syndrome
    2/13/2017

    XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that two leading experts in rheumatology, Robert Fox, MD and Simon Bowman, MD, have joined the Company's clinical advisory board to help guide a planned Phase II trial to evaluate the company's investigational drug, hCDR1, for the treatment of Sjögren's syndrome (SS)

  10. MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 With Halozyme PEGPH20
    2/13/2017

    MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical stage immuno-oncology drug development company, today announced results from a pre-clinical study evaluating the potential benefits of using MabVax's HuMab-5B1antibody, MVT-5873, currently in Phase I clinical trials for the treatment of metastatic pancreatic cancer with Halozyme Therapeutic's (NASDAQ: HALO) investigational drug PEGPH20, which targets the tumor microenvironment potentially allowing increased access of co-administered cancer drug therapies to solid tumors